SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001493152-21-029295
Filing Date
2021-11-19
Accepted
2021-11-19 09:00:37
Documents
63
Period of Report
2021-09-30

Document Format Files

Seq Description Document Type Size
1 form10-q.htm   iXBRL 10-Q 1965627
2 ex31-1.htm EX-31.1 10953
3 ex32-1.htm EX-32.1 5181
  Complete submission text file 0001493152-21-029295.txt   7056237

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE endv-20210930.xsd EX-101.SCH 54131
5 XBRL CALCULATION FILE endv-20210930_cal.xml EX-101.CAL 48626
6 XBRL DEFINITION FILE endv-20210930_def.xml EX-101.DEF 223100
7 XBRL LABEL FILE endv-20210930_lab.xml EX-101.LAB 420504
8 XBRL PRESENTATION FILE endv-20210930_pre.xml EX-101.PRE 309014
9 EXTRACTED XBRL INSTANCE DOCUMENT form10-q_htm.xml XML 1125871
Mailing Address 6320 CANOGA AVENUE 15TH FLOOR WOODLAND HILLS CA 91367
Business Address 6320 CANOGA AVENUE 15TH FLOOR WOODLAND HILLS CA 91367 (800) 489-4774
ENDONOVO THERAPEUTICS, INC. (Filer) CIK: 0001528172 (see all company filings)

IRS No.: 452552528 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 000-55453 | Film No.: 211426481
SIC: 2834 Pharmaceutical Preparations